Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_3
1
25%
Ph phase_4
2
50%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 42 (50.0%)

Trials by Status

not_yet_recruiting125%
terminated125%
completed250%

Recent Activity

0 active trials
Showing 4 of 4
not_yet_recruitingphase_4

Effect of Colchicine on Progression of Coronary Atherosclerosis in Patients With TET2-CHIP Variant

NCT07362966
terminatedphase_3

Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

NCT03403205
completedphase_2

Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients

NCT04475120
completedphase_4

Nephropathy In Type 2 Diabetes and Cardio-renal Events

NCT00535925

Clinical Trials (4)

Showing 4 of 4 trials
NCT07362966Phase 4

Effect of Colchicine on Progression of Coronary Atherosclerosis in Patients With TET2-CHIP Variant

Not Yet Recruiting
NCT03403205Phase 3

Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

Terminated
NCT04475120Phase 2

Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients

Completed
NCT00535925Phase 4

Nephropathy In Type 2 Diabetes and Cardio-renal Events

Completed

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4